Wilex Banks $17.5M Prometheus Payment for Rencarex Milestone
Opting for cash now rather than product sales later, Wilex AG decided to take a payment of $17.5 million as part of the deal it entered last year on the U.S. rights to its Phase III cancer antibody Rencarex (girentuximab) with Prometheus Laboratories Inc. It also stands to get another $2.5 million as part of a revised milestone payment that is contingent on a regulatory filing for the drug.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter